Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (371-380 of 598) with videos related to

Pageof 60
Sort By:
Therapeutic Advances in Hematology|June 17, 2024
Integrated genetic, epigenetic, and immune landscape of <i>TP53</i> mutant AML and higher risk MDS treated with azacitidineAmer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, et al.
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
Annals of Hematology|March 21, 2020
A 19-year-old patient with atypical chronic myeloid leukemiaPhilipp Ernst, Björn Engmann, Jochen J Frietsch, et al.
Haematologica|June 29, 2014
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemiaCatharina Müller-Thomas, Martina Rudelius, Ina-Christine Rondak, et al.
Experimental Hematology|February 5, 2022
Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessmentsAnita T Simonsen, Manja Meggendorfer, Marcus H Hansen, et al.
Seminars in Cancer Biology|June 27, 2021
Clinical utility of whole-genome sequencing in precision oncologyRichard Rosenquist, Edwin Cuppen, Reinhard Buettner, et al.
Blood|August 25, 2012
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Manja Meggendorfer, Andreas Roller, Torsten Haferlach, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
Blood|May 16, 2009
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndromeKen I Mills, Alexander Kohlmann, P Mickey Williams, et al.
Blood|August 24, 2012
A novel hierarchical prognostic model of AML solely based on molecular mutationsVera Grossmann, Susanne Schnittger, Alexander Kohlmann, et al.
Pageof 60

Showing results (371-380 of 598) with videos related to

Sort By:
Pageof 60
Therapeutic Advances in Hematology|June 17, 2024
Integrated genetic, epigenetic, and immune landscape of <i>TP53</i> mutant AML and higher risk MDS treated with azacitidineAmer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, et al.
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
Annals of Hematology|March 21, 2020
A 19-year-old patient with atypical chronic myeloid leukemiaPhilipp Ernst, Björn Engmann, Jochen J Frietsch, et al.
Haematologica|June 29, 2014
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemiaCatharina Müller-Thomas, Martina Rudelius, Ina-Christine Rondak, et al.
Experimental Hematology|February 5, 2022
Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessmentsAnita T Simonsen, Manja Meggendorfer, Marcus H Hansen, et al.
Seminars in Cancer Biology|June 27, 2021
Clinical utility of whole-genome sequencing in precision oncologyRichard Rosenquist, Edwin Cuppen, Reinhard Buettner, et al.
Blood|August 25, 2012
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Manja Meggendorfer, Andreas Roller, Torsten Haferlach, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
Blood|May 16, 2009
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndromeKen I Mills, Alexander Kohlmann, P Mickey Williams, et al.
Blood|August 24, 2012
A novel hierarchical prognostic model of AML solely based on molecular mutationsVera Grossmann, Susanne Schnittger, Alexander Kohlmann, et al.
Pageof 60